Biogen to acquire the remaining 89.8% stake in Sage Therapeutics in a $442m deal.

Synopsis

Biogen, a biotechnology company, offered to acquire the remaining 89.8% stake in Sage Therapeutics, a biopharmaceutical company, in a $442m deal.

Principals

Sage Therapeutics

Biogen

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy